Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-26
- Target Recruit Count
- 35
- Registration Number
- NCT00000686
- Locations
- 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-26
- Target Recruit Count
- 40
- Registration Number
- NCT00000988
- Locations
- 🇺🇸
Mount Sinai Med Ctr, New York, New York, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002420
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002418
- Locations
- 🇺🇸
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 94
- Registration Number
- NCT00001095
- Locations
- 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001091
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸State Univ of New York at Stony Brook, Stony Brook, New York, United States
🇺🇸Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States
A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 230
- Registration Number
- NCT00000789
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1750
- Registration Number
- NCT00000841
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 46
- Registration Number
- NCT00000822
- Locations
- 🇺🇸
Stanford CRS, Stanford, California, United States
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 10
- Registration Number
- NCT00000899
- Locations
- 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.